NCT04592601

Brief Summary

Assessment of Gastric Bypass combined with Vertical Sleeve Gastrectomy as primary treatment for patients with severe clinical obesity. Average percentage of total weight loss and percentage excess weight loss will be computed at 6 months, one year and then annually. Comorbid conditions, quality of life measures, appetite and satiety measures and adverse events will be tracked.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2020

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 7, 2020

Completed
12 days until next milestone

First Posted

Study publicly available on registry

October 19, 2020

Completed
7 days until next milestone

Study Start

First participant enrolled

October 26, 2020

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

October 19, 2020

Status Verified

October 1, 2020

Enrollment Period

1.2 years

First QC Date

October 7, 2020

Last Update Submit

October 14, 2020

Conditions

Keywords

ObesitySurgeryBariatric SurgeryMorbid ObesityGastric BypassSleeve GastrectomySLIMMS

Outcome Measures

Primary Outcomes (1)

  • Weight Loss

    Primary efficacy variable is Weight Loss Weight loss will be measured as: 1. Pounds lost (pre-op weight - post-op weight) 2. Total Weight Loss, calculated as (Pre-op Weight-Current Weight) in pounds (lb) 3. Percent Excess Weight Loss, calculated as \[(Pre-op Weight - Ideal Body Weight)/Ideal Body Weight\] x 100. Ideal Body Weight calculated using the universal IBW formula.

    6 months, 12 months and 2 years

Secondary Outcomes (3)

  • Metabolic Comorbidity

    2 Years

  • Changes in Quality of Life from baseline

    2 Years

  • Adverse Events

    2 Years

Study Arms (1)

S.L.I.M.M.S. Procedure

EXPERIMENTAL

Prospective collection of data on the safety and efficacy of the S.L.I.M.M.S. Procedure

Procedure: S.L.I.M.M.S. Procedure

Interventions

Combined Gastric Bypass with Vertical Sleeve Gastrectomy

Also known as: Bariatric Surgery
S.L.I.M.M.S. Procedure

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Be between 18 and 65 years of age
  • Have a body mass index of equal to or above 35 kgs per m2
  • Have identifiable obesity-related comorbidity; medical, physical or psycho-social
  • A history of attempts at weight reduction within the past five-year period
  • Ability to understand the non-surgical and surgical options for weight loss
  • Understand the behavioral changes needed to maximize surgical weight loss success
  • Agree to comply with recommended follow-up clinical assessments
  • Agree to comply with lifelong nutritional supplementation

You may not qualify if:

  • Lack of ability to understand weight loss options and requirements for long-term success with surgery
  • Inability to understand and accept the risks and potential benefits
  • Inability to understand and agree to the compliance requirements of the study
  • Prior gastric surgery including all forms of bariatric surgical or endoscopic procedures
  • A history of previous abdominal surgery which precludes gastric bypass
  • Medical contra-indications to bariatric surgery
  • Dementia, active psychosis, unstable psychiatric disease
  • Concurrent experimental drug use
  • Pregnancy or intending to conceive within 12 months or current breast-feeding
  • Recreational drug use or excessive alcohol intake
  • Use of drugs known to affect body composition
  • Use of cytotoxic drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

The N.E.W. Program, Inc.

Newport Beach, California, 92663, United States

Location

Foothill Regional Medical Center

Tustin, California, 92780, United States

Location

MeSH Terms

Conditions

Obesity, MorbidMetabolic SyndromeInsulin ResistanceObesity

Interventions

Bariatric Surgery

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic Diseases

Intervention Hierarchy (Ancestors)

BariatricsObesity ManagementTherapeuticsSurgical Procedures, Operative

Study Officials

  • BRIAN QUEBBEMANN, M.D.

    The N.E.W. Program, Inc.

    PRINCIPAL INVESTIGATOR

Central Study Contacts

BRIAN QUEBBEMANN, M.D.

CONTACT

Jennifer Ausdemore, MHA

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Prospective Single Group Clinical Trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

October 7, 2020

First Posted

October 19, 2020

Study Start

October 26, 2020

Primary Completion

December 31, 2021

Study Completion

December 31, 2022

Last Updated

October 19, 2020

Record last verified: 2020-10

Data Sharing

IPD Sharing
Will not share

Locations